NASDAQ:GILD - Gilead Sciences Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$75.59 +0.75 (+1.00 %)
(As of 08/16/2018 04:00 PM ET)
Previous Close$74.84
Today's Range$74.68 - $75.68
52-Week Range$64.27 - $89.54
Volume8.71 million shs
Average Volume7.59 million shs
Market Capitalization$99.47 billion
P/E Ratio8.83
Dividend Yield2.95%
Beta1.03
Gilead Sciences logoGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen Sciences Ireland UC, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GILD
CUSIP37555810
Phone650-574-3000

Debt

Debt-to-Equity Ratio1.23
Current Ratio3.00
Quick Ratio2.92

Price-To-Earnings

Trailing P/E Ratio8.83
Forward P/E Ratio11.52
P/E Growth-5.85

Sales & Book Value

Annual Sales$26.11 billion
Price / Sales3.75
Cash Flow$9.4843 per share
Price / Cash7.97
Book Value$15.69 per share
Price / Book4.82

Profitability

EPS (Most Recent Fiscal Year)$8.56
Net Income$4.63 billion
Net Margins9.52%
Return on Equity41.57%
Return on Assets13.79%

Miscellaneous

Employees10,000
Outstanding Shares1,296,340,000
Market Cap$99.47 billion

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Wednesday, July 25th. Stockholders of record on Friday, September 14th will be paid a dividend of $0.57 per share on Thursday, September 27th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date is Thursday, September 13th. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) posted its quarterly earnings data on Wednesday, July, 25th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.56 by $0.35. The biopharmaceutical company earned $5.65 billion during the quarter, compared to the consensus estimate of $5.20 billion. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. The business's revenue was down 20.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.56 EPS. View Gilead Sciences' Earnings History.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Thursday, October, 25th 2018. View Earnings Estimates for Gilead Sciences.

What price target have analysts set for GILD?

24 analysts have issued 12 month price targets for Gilead Sciences' stock. Their forecasts range from $72.00 to $105.00. On average, they expect Gilead Sciences' share price to reach $87.9414 in the next twelve months. This suggests a possible upside of 16.3% from the stock's current price. View Analyst Price Targets for Gilead Sciences.

What is the consensus analysts' recommendation for Gilead Sciences?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 10 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gilead Sciences.

What are Wall Street analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:
  • 1. According to Zacks Investment Research, "Gilead is now banking on its HIV franchise and newer avenues like the CAR-T therapy to drive growth. The HIV franchise maintains momentum driven by the rapid adoption of Descovy-based regimens. The FDA approval of Biktarvy has further widened the portfolio. Biktarvy has also been approved in Europe which should boost sales further. The initial uptake of Yescarta is encouraging in the United States and the CHMP gave a positive opinion on the same. Meanwhile, Gilead is intending to foray into the NASH market with selonsertib and filgotinib. Both the candidates are being evaluated in late stage studies and a tentative approval will diversify Gilead’s portfolio. Shares have outperformed the industry in the year so far. Estimates for Q2 are up by two cents in the last thirty days ahead of the results (scheduled for July 25). However, Gilead’s HCV franchise is under pressure due to competitive and pricing pressure." (7/18/2018)
  • 2. Needham & Company LLC analysts commented, "Gilead reported $5.09B 1Q18 total revenue, below our $5.52B and consensus $5.3B ests. Product sales were $5.00B, below our $5.41B est. Gilead continues to lose share to Abbvie in HCV. Trend is worrisome, although mgmt still guiding for market share stabilization mid-2018. HIV sales in 1Q18 also disappointed, reportedly driven by bigger than expected seasonal inventory draw-down and generic TDF. Growth in HIV (i.e. Biktarvy success) is critical. NASH program has not yet distinguished itself, awaiting data from selonsertib Phase 3 trials (1H19) and 48wk combination Phase 2 trials (2020). Yescarta and cell therapy programs are in early stages." (5/2/2018)
  • 3. Leerink Swann analysts commented, "RARE’s 4Q report this afternoon was relatively in line with expectations. Incremental clinical updates for burosumab in young children and in adults with osteomalacia (bone softening) in the report further support the drug’s utility in both populations. The year ahead is shaping up to be catalyst-rich for RARE, with data from two gene therapy programs, the Phase 3 of trihep in Glut1 DS, and a decision on trihep registration plans in FAOD expected over the coming months. Although we continue to expect a slow rollout of burosumab (PDUFA date 4/17/18) and Mepsevii, we see opportunity for further upside in shares over the course of 2018. Maintain OW." (2/22/2018)
  • 4. BMO Capital Markets analysts commented, "Early biopotency signals from a single patient dosed with ABO-101 (for Sanfilippo B), demonstrate targeted reduction on toxic sugars." (2/7/2018)

Are investors shorting Gilead Sciences?

Gilead Sciences saw a increase in short interest in July. As of July 13th, there was short interest totalling 15,410,952 shares, an increase of 12.5% from the June 29th total of 13,701,705 shares. Based on an average trading volume of 6,413,971 shares, the short-interest ratio is currently 2.4 days. Approximately 1.2% of the shares of the stock are short sold. View Gilead Sciences' Current Options Chain.

Who are some of Gilead Sciences' key competitors?

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:
  • Dr. John F. Milligan, CEO, Pres & Director (Age 57)
  • Ms. Robin L. Washington, CFO & Exec. VP (Age 55)
  • Mr. Kevin B. Young, Advisory (Age 60)
  • Dr. John G. McHutchison, Exec. VP of Research, Clinical R&D and Chief Scientific Officer
  • Mr. Brett A. Pletcher, Exec. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.

Has Gilead Sciences been receiving favorable news coverage?

Media stories about GILD stock have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Gilead Sciences earned a news and rumor sentiment score of 0.12 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 46.11 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Gilead Sciences.

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.12%), Bank of New York Mellon Corp (2.38%), FMR LLC (1.51%), Parnassus Investments CA (1.50%), Sanders Capital LLC (0.81%) and Boston Partners (0.64%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Which major investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Bank of Nova Scotia, Caisse DE Depot ET Placement DU Quebec, American Century Companies Inc., ANTIPODES PARTNERS Ltd, Oppenheimer & Co. Inc. and Morgan Stanley. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

Which major investors are buying Gilead Sciences stock?

GILD stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Natixis, Los Angeles Capital Management & Equity Research Inc., Sanders Capital LLC, Unigestion Holding SA, Diamond Hill Capital Management Inc., Envestnet Asset Management Inc. and Janus Henderson Group PLC. View Insider Buying and Selling for Gilead Sciences.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $75.59.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $99.47 billion and generates $26.11 billion in revenue each year. The biopharmaceutical company earns $4.63 billion in net income (profit) each year or $8.56 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]


MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  1,830 (Thanks for Voting!)
Underperform Votes:  760 (Thanks for Voting!)
Total Votes:  2,590
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.